We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Secukinumab 300 mg administered with an auto-injector ...

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...

RICHMOND, Va.--(BUSINESS WIRE)--Please replace the release dated March 2, 2022, with the following corrected version due to multiple revisions. The updated release ...

The auto injector market represents a rapidly expanding segment within the global pharmaceutical delivery systems industry, driven by the increasing prevalence of chronic diseases and the growing ...